A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Phase 1
110
about 3.4 years
18+
18 sites in CA, CO, FL +9
About this study
This trial is testing a treatment called ALTA2618 for adults with advanced solid tumors that have the AKT1 E17K mutation. The goal is to learn about how safe and effective ALTA2618 is in these patients.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take ALTA2618
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Adverse Events, Dose Limiting Toxicities
Secondary: Duration of Response (DOR), Maximum Observed Plasma Concentration (Cmax), Overall Response Rate (ORR), Overall Survival (OS), Progression-Free Survival (PFS), Terminal Half-Life (t1/2), Time to Reach Maximum Observed Plasma Concentration (Tmax)
Oncology